The EU four-year project ELSAH, which began at the dawn of 2019, aims to design a wearable to enable continuous determination of biomarker concentrations. Project coordinator Dr Joerg Schotter, Molecular Diagnostics, Centre for Health & Bioresources, AIT Austrian Institute of Technology GmbH, explains the project’s objectives and potential applications for the planned wearable.
Early non-invasive detection of kidney rejection after transplantation was the central aim of a collaboration between Prof. Dr. Bernhard Banas, Chairman of Nephrology at the University Hospital Regensburg (UKR) and the medical diagnostics company, numares. The results of their joint clinical trial “UMBRELLA” were just published in EBioMedicine and presented at the American Society of…
Breast cancer could be detected up to five years before there are any clinical signs of it, using a blood test that identifies the body’s immune response to substances produced by tumour cells, according to new research presented at the 2019 NCRI Cancer Conference. Cancer cells produce proteins called antigens that trigger the body to make antibodies against them – autoantibodies. Researchers…
Spanish researchers in Valencia have identified specific fragments of genetic material that play a role in the development of respiratory failure and sepsis in pneumonia patients. Presenting the research at the European Respiratory Society International Congress, Dr Francisco Sanz said the findings could enable doctors to test quickly for these biological markers when a patient is admitted to…
An international research group at the Max Planck Institute for Biological Cybernetics developed a brain imaging method for improved and early assessment of stroke. Their study presents a methodology which monitors calcium ion fluctuations in the brain using a molecular functional MRI approach.
Technology developed using artificial intelligence (AI) could identify people at high risk of a fatal heart attack at least five years before it strikes, according to new research funded by the British Heart Foundation (BHF). The findings are being presented at the European Society of Cardiology (ESC) Congress in Paris and published in the European Heart Journal. Researchers at the University of…
Levels of molecules associated with genetic function, such as microRNA, can be an important indicator of abnormal activity associated with cancer. However, little is known about how different molecules are altered in cancerous cells. Now, researchers from Japan have found a new way of distinguishing cancerous from non-cancerous tissues. In a study published in Nature Communications, researchers…
Fourteen metabolic biomarkers can predict long term mortality in individuals helping to determine life expectancy in general populations, a new study in the journal Nature Communications reports. In the largest study of its kind, researchers from Leiden University Medical Center in the Netherlands and the University of Surrey investigated predictors of long-term mortality risk. Current predictors…
In a new study, led by the University of Glasgow, scientists show that brain activity recorded using functional magnetic resonance imaging (fMRI) may help predict response to CBT in depression before the treatment commences. The advances could help patients receive the most appropriate treatment for depression in a timely manner.
Our eyes – considered by many to be the windows to the soul – need constant care, and as we age, they sometimes also need significant repair. The panes of these windows – the corneas – are transparent tissues that have been the focus of some of the oldest and most common transplantation surgeries. Now thanks to researchers in Kyoto, some such transplants may become even safer. The team,…
Using artificial intelligence (AI) to push development of imaging biomarkers shows great promise to improve disease understanding. This alliance could be a game changer in healthcare but, to advance research, clinical validation and variability of results must be factored in, a prominent Spanish radiologist advises. In clinical practice efforts are already ongoing to apply AI to obtain new…
The team of the Heinz Nixdorf Chair of Biomedical Electronics at the Technical University of Munich focuses on innovative diagnostic tools to accelerate the development towards personalized medicine. Therapies tailored to the individual patient – this is the future not only of oncology but of many medical disciplines. “At this point, however,” concedes Professor Dr Oliver Hayden,…
The use of troponin assays to rule in or rule out myocardial infarction (MI) rapidly is critical on several levels. The quick result can reassure the patient that they have not had a heart attack and can return home safely; or, in the event of MI, the relevant treatment can start very soon. It also ensures that clinicians can make the right decision with confidence. Troponin levels have been the…
Advancing technology is allowing scientists increasingly to search for tiny signs of cancer and other health issues in samples of patients’ blood and urine. These “liquid biopsies” are less invasive than a traditional biopsy, and can provide information about what’s happening throughout the body instead of just at a single site. Now researchers at the University of Michigan Rogel Cancer…
Cognitive impairment associated with cancer, also known as “chemobrain”, has gained recognition as a complication of the disease and its treatment, as it can negatively affect the daily lives of cancer patients and survivors. Chemobrain can be subtle yet persistent, with some cancer patients reporting difficulties related to memory and attention even months after completing their treatment.…
A major milestone on its strategic mission to lead in sepsis diagnostics, Beckman Coulter announced that its Early Sepsis Indicator has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Sepsis is a global healthcare crisis that affects more than 30 million people worldwide. The Early Sepsis Indicator is a first-of-its-kind, hematology-based cellular biomarker that is…
Test more accurately identifies four mutations for which FDA-approved drugs exist and offers faster turn-around time between initial testing and commencement of therapy.
Forty-two percent of all deaths in the United States are related to cardiovascular disease (CVD). According to the Global Cardiovascular Drugs Market Forecast, by 2030 the number of deaths from CVD will rise to 23.6 million per year in the U.S. alone. Along with increased deaths, spending on drugs to treat CVD as well as related hospital stays, home health care and lost productivity will also…
Flow cytometry has proved an invaluable diagnostic tool for leukaemia and lymphoma for almost three decades. Now, however, this is evolving in applications to seek out residual disease in cases and in fusion with molecular testing to advance its diagnostic potential. However, although recognised as fast, flexible and accurate, flow cytometry suffers from a lack of standardisation, according to…
It is non-invasive, delivers a chance of early diagnosis, prognostic information and sequential monitoring, and, believes Professor Francesco Salvatore, the enormous potential of liquid biopsies has still to be reached. However, the positive results obtained so far have ‘opened the door to a promising new multi-faceted group of tumour markers, at present collectively designated “liquid…
A commonly used biomarker of kidney disease may also indicate lung problems, particularly COPD, or chronic obstructive pulmonary disease, according to new research published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine. In “Albuminuria, Lung Function Decline, and Risk of Incident COPD: the NHLBI Pooled Cohorts Study,” Elizabeth C.…
Researchers at Cleveland Clinic, University of Oxford, and University of Erlangen have identified a novel imaging biomarker – and found it can be used to predict all-cause and cardiac mortality by measuring inflammation of fatty tissue surrounding the coronary arteries.
A range of new biomarkers and diagnostics for precision cardiovascular medicine were outlined in a session at the British Cardiovascular Society annual conference held recently in Manchester. Speakers from King’s British Heart Foundation Centre looked at how mass spectrometry allows clinicians to measure large numbers of proteins simultaneously, discussed a new biomarker for cardiac ischaemia…
Taking a biopsy of a brain tumor is a complicated and invasive surgical process, but a team of researchers at Washington University in St. Louis is developing a way that allows them to detect tumor biomarkers through a simple blood test. Hong Chen, a biomedical engineer, and Eric C. Leuthardt, MD, a neurosurgeon, led a team of engineers, physicians and researchers who have developed a…
ProteoMediX AG announced results from a retrospective study that showed the correlation of its prostate cancer diagnosis test with cancer aggressiveness in patients scheduled for prostate biopsies. The study findings presented at the 2018 European Association of Urology (EAU) congress in Copenhagen, Denmark showed that the test has the potential to avoid a large number of biopsies. “Correlation…